Janssen persuades Scotland to reimburse Zytiga
This article was originally published in Scrip
Executive Summary
Janssen has managed to convince the Scottish Medicines Consortium, Scotland's health technology appraisal body, that the benefits of its anticancer Zytiga (abiraterone) do in fact justify the cost. The consortium has this week accepted the drug for use on the Scottish NHS for patients with metastatic castration resistant prostate cancer.